{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:26:20Z","timestamp":1792167980218,"version":"4.4.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.coph.2024.102431","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:26:39Z","timestamp":1706174799000},"page":"102431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Novel treatments for dry eye syndrome"],"prefix":"10.1016","volume":"75","author":[{"given":"Esther","family":"Roucaute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Huertas-Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-2558","authenticated-orcid":false,"given":"Alfonso L.","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2024.102431_bib1","article-title":"Dry eye disease severity and impact on quality of life in type II diabetes mellitus","volume":"10","author":"Zhmud","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.coph.2024.102431_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/aos.15049","article-title":"The association between visual display terminal use and dry eye: a review","volume":"100","author":"Fjaervoll","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajo.2022.10.019","article-title":"What are the dry eye questionnaires available in the scientific literature used for? A scoping review","volume":"246","author":"Sanchez-Brau","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib4","first-page":"1","article-title":"Real life impact of dye eye disease","author":"Cutrupi","year":"2023","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10384-020-00798-1","article-title":"Heterogeneity of eye drop use among symptomatic dry eye individuals in Japan: large-scale crowdsourced research using DryEyeRhythm application","volume":"65","author":"Eguchi","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib6","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.4103\/IJO.IJO_3359_22","article-title":"Study of dry eye syndrome: focus on causative factors, treatment modalities, quality of life, and preservatives used in eye drops","volume":"71","author":"Raval","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jtos.2022.07.007","article-title":"Topical glaucoma medications - clinical implications for the ocular surface","volume":"26","author":"Fineide","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.coph.2024.102431_sref8","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4103\/IJO.IJO_2818_22","article-title":"Role of topical and systemic immunosuppression in aqueous-deficient dry eye disease","volume":"71","author":"Kate","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/1319-4534.337849","article-title":"Dry eye syndrome risk factors: a systemic review","volume":"35","author":"Hasan ZA","year":"2021","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib10","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4103\/IJO.IJO_2887_22","article-title":"Hormones and dry eye disease","volume":"71","author":"Gorimanipalli","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065609","article-title":"Expression of androgen and estrogen receptors in the human lacrimal gland","volume":"24","author":"Hat","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2024.102431_bib12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4103\/IJO.IJO_3406_22","article-title":"Refractive surgery and dry eye - an update","volume":"71","author":"Nair","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/life12111899","article-title":"Ophthalmological approach for the diagnosis of dry eye disease in patients with Sjogren's syndrome","volume":"12","author":"Barrientos","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.coph.2024.102431_sref14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/eye.2016.54","article-title":"The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjogren's syndrome: a pilot study","volume":"30","author":"Yokoi","year":"2016","journal-title":"Eye"},{"key":"10.1016\/j.coph.2024.102431_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","article-title":"Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape","volume":"12","author":"Sheppard","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.coph.2024.102431_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/07853890.2022.2157477","article-title":"Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists","volume":"55","author":"Sheppard","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.coph.2024.102431_bib17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/aos.15150","article-title":"Review on the possible pathophysiological mechanisms underlying visual display terminal-associated dry eye disease","volume":"100","author":"Fjaervoll","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref18","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.4103\/IJO.IJO_2808_22","article-title":"Aqueous-deficient dry eye disease: preferred practice pattern guidelines on clinical approach, diagnosis, and management","volume":"71","author":"Donthineni","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib19","article-title":"A\u00a0review of diagnostic tests for qualitative and quantitative tear film deficiency in dogs","author":"Iwashita","year":"2022","journal-title":"Vet Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib20","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4103\/IJO.IJO_2841_22","article-title":"Evaporative dry eye disease due to meibomian gland dysfunction: preferred practice pattern guidelines for diagnosis and treatment","volume":"71","author":"Narang","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/aos.15159","article-title":"Hyaluronic acid in the treatment of dry eye disease","volume":"100","author":"Hynnekleiv","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030990","article-title":"A\u00a0review on dry eye disease treatment: recent progress, diagnostics, and future perspectives","volume":"15","author":"Mondal","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.coph.2024.102431_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/iovs.64.1.5","article-title":"Dry Eye A, et\u00a0al. Association of Tear Osmolarity With Signs and Symptoms of Dry Eye Disease in the Dry Eye Assessment and Management (DREAM) Study","volume":"64","author":"Greiner","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2024.102431_sref24","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109418","article-title":"Cyclosporin A improves the hyperosmotic response in an experimental dry eye model by inhibiting the HMGB1\/TLR4\/NF-kappaB signaling pathway","volume":"229","author":"Shen","year":"2023","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2024.102431_bib25","first-page":"CD015070","article-title":"Topical corticosteroids for dry eye","volume":"10","author":"Liu","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2024.102431_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1089\/jop.2022.0133","article-title":"Anti-inflammatories in the treatment of dry eye disease: a review","volume":"39","author":"Perez","year":"2023","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2024.102431_sref27","first-page":"40","article-title":"A\u00a0water-free 0.1%Cyclosporine ASolution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.coph.2024.102431_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12886-023-02798-4","article-title":"Simple surgical punctal occlusion with high frequency radiowave electrosurgery","volume":"23","author":"Park","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib29","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/11206721221141481","article-title":"Management of inflammation in dry eye disease: recommendations from a European panel of experts","volume":"33","author":"Messmer","year":"2023","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/bjophthalmol-2019-315747","article-title":"Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review","volume":"105","author":"Aragona","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020292","article-title":"Oxidative stress in the anterior ocular diseases: diagnostic and treatment","volume":"11","author":"Dammak","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.coph.2024.102431_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/aos.13436","article-title":"Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting","volume":"96","author":"Baudouin","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.coph.2024.102431_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.clae.2023.101837","article-title":"The epidemiology of dry eye disease in the UK: the Aston dry eye study","author":"Vidal-Rohr","year":"2023","journal-title":"Contact Lens Anterior Eye"},{"key":"10.1016\/j.coph.2024.102431_sref35","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.833778","article-title":"Demodex folliculorum infestation in meibomian gland dysfunction related dry eye patients","volume":"9","author":"Hao","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.coph.2024.102431_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.10.14.6","article-title":"Changes in meibum lipid composition with ocular demodex infestation","volume":"10","author":"Gao","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.coph.2024.102431_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015595","article-title":"The correlation between the microstructure of meibomian glands and ocular Demodex infestation: a retrospective case-control study in a Chinese population","volume":"98","author":"Cheng","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.coph.2024.102431_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2019.03.007","article-title":"Demodex mite infestation and its associations with tear film and ocular surface parameters in patients with ocular discomfort","volume":"204","author":"Rabensteiner","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref39","first-page":"1","article-title":"Treatment of demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle","author":"Yeu","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.coph.2024.102431_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jdsr.2019.09.006","article-title":"B\u00a0cell dysregulation in primary Sjogren's syndrome: a review","volume":"55","author":"Ibrahem","year":"2019","journal-title":"Jpn Dent Sci Rev"},{"key":"10.1016\/j.coph.2024.102431_bib41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/ICO.0000000000001865","article-title":"Sjogren's syndrome: more than just dry eye","volume":"38","author":"Akpek","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.coph.2024.102431_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010147","article-title":"Management of Sjogren's dry eye disease-advances in ocular drug delivery offering a new hope","volume":"15","author":"Wu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.coph.2024.102431_sref43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/ACI.0000000000000841","article-title":"Neurostimulation for dry eye disease","volume":"22","author":"Erdinest","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2024.102431_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10070497","article-title":"Corneal in\u00a0vivo laser-scanning confocal microscopy findings in dry eye patients with Sjogren's syndrome","volume":"10","author":"Matsumoto","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.coph.2024.102431_bib45","article-title":"Evidence of disruption in neural regeneration in dry eye secondary to rheumatoid arthritis","volume":"24","author":"Sonkodi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2024.102431_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.108944","article-title":"Pathophysiology of dry eye disease and novel therapeutic targets","volume":"217","author":"Messmer","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.coph.2024.102431_bib47","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0000000000003069","article-title":"Elevated neuropeptides in dry eye disease and their clinical correlations","volume":"42","author":"Yang","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.coph.2024.102431_bib48","article-title":"Recovery of corneal innervation after treatment in dry eye disease: a confocal microscopy study","volume":"12","author":"Barros","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.coph.2024.102431_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ICL.0000000000000953","article-title":"The gut-eye Axis: correlation between the gut microbiota and autoimmune dry eye in individuals with sjogren syndrome","volume":"49","author":"Bai","year":"2023","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.coph.2024.102431_bib50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.survophthal.2021.03.010","article-title":"The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders","volume":"66","author":"Aragona","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228443","article-title":"Can gut microbiota affect dry eye syndrome?","volume":"21","author":"Moon","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2024.102431_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.716867","article-title":"Comparison of the ocular microbiomes of dry eye patients with and without autoimmune disease","volume":"11","author":"Qi","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.coph.2024.102431_bib53","article-title":"Microbiome and immune-mediated dry eye: a review","volume":"7","author":"Watane","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib54","first-page":"13","article-title":"Ocular surface microbiota in diabetic patients with dry eye disease","volume":"62","author":"Zhang","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2024.102431_bib55","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A\u00a0review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113267","article-title":"Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: process optimization through response surface methodology (RSM) and biocompatibility evaluation","volume":"225","author":"Li","year":"2023","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.coph.2024.102431_bib57","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A\u00a0clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coph.2024.102431_bib58","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.1038\/srep12968","article-title":"Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation","volume":"5","author":"Guo","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2024.102431_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12886-023-02838-z","article-title":"Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial","volume":"23","author":"Rao","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/0976-500X.195920","article-title":"Lifitegrast: a novel drug for treatment of dry eye disease","volume":"7","author":"Abidi","year":"2016","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.coph.2024.102431_bib61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jop.2016.0105","article-title":"LFA-1\/ICAM-1 interaction as a therapeutic target in dry eye disease","volume":"33","author":"Pflugfelder","year":"2017","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2024.102431_bib62","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.2147\/OPTH.S327691","article-title":"A\u00a0post-acute ocular tolerability comparison of topical Reproxalap 0.25% and lifitegrast 5% in patients with dry eye disease","volume":"15","author":"McMullin","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib63","article-title":"Lifitegrast ophthalmic solution 5% is a safe and efficient eyedrop for dry eye disease: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.coph.2024.102431_bib64","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coph.2024.102431_bib65","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-022-01782-4","article-title":"Varenicline solution nasal spray: a review in dry eye disease","volume":"82","author":"Frampton","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2024.102431_bib66","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.clinthera.2022.09.013","article-title":"Bilateral effect of OC-01 (varenicline solution) nasal spray for treatment of signs and symptoms in individuals with mild, moderate, and severe dry eye disease","volume":"44","author":"Katz","year":"2022","journal-title":"Clin Therapeut"},{"issue":"2","key":"10.1016\/j.coph.2024.102431_sref67","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/OPX.0000000000001986","article-title":"Does dry eye disease severity impact efficacy of varenicline solution nasal spray on sign and symptom treatment outcomes?","volume":"100","author":"Sheppard","year":"2023","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.coph.2024.102431_bib68","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0215","article-title":"Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease","author":"Hauswirth","year":"2023","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.coph.2024.102431_bib69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/OPTH.S323301","article-title":"Practical guidance for the use of Loteprednol etabonate ophthalmic suspension 0.25% in the management of dry eye disease","volume":"16","author":"Venkateswaran","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib70","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.coph.2024.102431_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaophthalmol.2023.0270","article-title":"Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients: a randomized clinical trial","volume":"141","author":"Tian","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib73","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jop.2019.0092","article-title":"Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial","volume":"36","author":"Schmidl","year":"2020","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.coph.2024.102431_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.709712","article-title":"Deciphering the action of perfluorohexyloctane eye drops to reduce ocular discomfort and pain","volume":"8","author":"Delicado-Miralles","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.coph.2024.102431_bib75","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.coph.2024.102431_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study: NOV03 for dry eye disease associated with meibomian gland","author":"Sheppard","year":"2023","journal-title":"Dysfunction Am J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib77","first-page":"42","article-title":"Lotilaner ophthalmic solution, 0.25%, for the treatment of demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1)","author":"Yeu","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.coph.2024.102431_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/tvst.9.12.23","article-title":"Novel extranasal tear stimulation: pivotal study results","volume":"9","author":"Ji","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.coph.2024.102431_sref79","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.oftal.2023.01.008","article-title":"Effectiveness of topical insulin for the treatment of surface corneal pathologies","volume":"98","author":"Castro Mora","year":"2023","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.coph.2024.102431_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/IOP.0000000000002146","article-title":"The role of insulin-like growth factor-1 and its receptor in the eye: a review and implications for IGF-1R inhibition","volume":"39","author":"Truong","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.coph.2024.102431_bib81","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/ACI.0000000000000770","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"21","author":"Cui","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2024.102431_bib82","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4103\/IJO.IJO_2756_22","article-title":"Autologous serum eye drops in dry eye disease: preferred practice pattern guidelines","volume":"71","author":"Vazirani","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/vox.13413","article-title":"Eye drops of human origin-Current status and future needs: report on the workshop organized by the ISBT Working Party for Cellular Therapies","volume":"118","author":"Gabriel","year":"2023","journal-title":"Vox Sang"},{"key":"10.1016\/j.coph.2024.102431_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08820538.2023.2168485","article-title":"Can nerve growth factor (NGF) Be a treatment option for pediatric eye diseases?","volume":"38","author":"Yavuz Saricay","year":"2023","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib85","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICU.0000000000000768","article-title":"Alternative therapies for dry eye disease","volume":"32","author":"Mittal","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajo.2023.01.025","article-title":"Cost and prescriber and patient characteristics of cenegermin use in the medicare population","volume":"250","author":"Dai","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref87","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1159\/000525923","article-title":"Neurotrophic keratopathy treated with topical recombinant human nerve growth factor (cenegermin): case series study with long-term follow-up","volume":"13","author":"Garcia-Delpech","year":"2022","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib88","article-title":"Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy","volume":"14","author":"Arboleda","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib89","article-title":"Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: retrospective case series of cenegermin treatment","volume":"27","author":"Epitropoulos","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.coph.2024.102431_bib90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ajo.2021.04.023","article-title":"Clinically relevant activity of the novel RASP inhibitor Reproxalap in allergic conjunctivitis: the phase 3 ALLEVIATE trial","volume":"230","author":"Clark","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref91","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajo.2021.01.011","article-title":"Early onset and broad activity of Reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease","volume":"226","author":"Clark","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib92","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1167\/iovs.12-11515","article-title":"Neutralization of ocular surface TNF-alpha reduces ocular surface and lacrimal gland inflammation induced by in\u00a0vivo dry eye","volume":"54","author":"Ji","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2024.102431_sref93","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s10792-022-02245-1","article-title":"TNF-alpha inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China","volume":"42","author":"Dong","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib94","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/02713683.2018.1461909","article-title":"Efficacy of HL036 versus cyclosporine A in the treatment of naturally occurring canine keratoconjunctivitis sicca","volume":"43","author":"Lee","year":"2018","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.coph.2024.102431_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314947","article-title":"A\u00a0new organotypic 3D slice culture of mouse meibomian glands reveals impact of melanocortins","volume":"23","author":"Zahn","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2024.102431_bib96","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3389\/fphar.2018.01535","article-title":"Probing the role of melanocortin type 1 receptor agonists in diverse immunological diseases","volume":"9","author":"Spana","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2024.102431_bib97","article-title":"Effectiveness of PL9643 in treating the signs and symptoms of moderate to severe dry eye disease including a subpopulation of hyper-responders to CAE\u00ae challenge: results from 2 independent clinical trials","author":"Ousler","year":"2023","journal-title":"View Presentation. ARVO"},{"key":"10.1016\/j.coph.2024.102431_bib98","article-title":"Efficacy and safety of the melanocortin agonist PL9643 in a phase 2 study of subjects with dry eye disease","author":"Kenyon","year":"2021","journal-title":"ARVO"},{"key":"10.1016\/j.coph.2024.102431_bib99","doi-asserted-by":"crossref","DOI":"10.15761\/ICM.1000124","article-title":"Development of tivanisiran, a topical siRNA designed to treat dry eye disease","volume":"2","author":"Bleau","year":"2018","journal-title":"Integrative Clinical Medicine"},{"key":"10.1016\/j.coph.2024.102431_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2024.102431_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112618","article-title":"Recent progress in TRPM8 modulation: an update","volume":"20","author":"Gonzalez-Muniz","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2024.102431_bib102","article-title":"Topical TRPM8 agonist for relieving neuropathic ocular pain in patients with dry eye: a pilot study","volume":"10","author":"Yoon","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.coph.2024.102431_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ph11040125","article-title":"TRPM8 channels and dry eye","volume":"11","author":"Yang","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.coph.2024.102431_bib104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12886-017-0495-2","article-title":"A\u00a0novel TRPM8 agonist relieves dry eye discomfort","volume":"17","author":"Yang","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_sref105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","article-title":"A\u00a0randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)","volume":"26","author":"Wirta","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.coph.2024.102431_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040906","article-title":"Characterization and HPLC analysis of the (1S,2S,5R)-Diastereomer and the enantiomer of the clinical candidate AR-15512","volume":"26","author":"Rodriguez-Arevalo","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.coph.2024.102431_bib107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40123-018-0158-2","article-title":"The role of SKQ1 (visomitin) in inflammation and wound healing of the ocular surface","volume":"8","author":"Wei","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.coph.2024.102431_bib108","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s12325-015-0273-6","article-title":"Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome","volume":"32","author":"Brzheskiy","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.coph.2024.102431_bib109","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1134\/S0006297914100113","article-title":"Preventive and therapeutic effects of SkQ1-containing Visomitin eye drops against light-induced retinal degeneration","volume":"79","author":"Novikova","year":"2014","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.coph.2024.102431_bib110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2024.102431_bib111","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B\u00a0cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2024.102431_bib112","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.4103\/IJO.IJO_2981_22","article-title":"Tear biomarkers in dry eye disease: progress in the last decade","volume":"71","author":"Kumar","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib113","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1167\/iovs.11-9417","article-title":"Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease","volume":"53","author":"Na","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2024.102431_bib114","volume":"127","author":"Goyal","year":"2009"},{"key":"10.1016\/j.coph.2024.102431_bib115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/mi.2009.21","article-title":"Role of Th17 cells in the immunopathogenesis of dry eye disease","volume":"2","author":"Chauhan","year":"2009","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coph.2024.102431_bib116","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41419-020-02891-2","article-title":"Small molecules targeting RORgammat inhibit autoimmune disease by suppressing Th17 cell differentiation","volume":"11","author":"Tan","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coph.2024.102431_bib117","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.4049\/jimmunol.1502641","article-title":"IL-17 augments B cell activation in ocular surface autoimmunity","volume":"197","author":"Subbarayal","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coph.2024.102431_bib118","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41467-020-20385-9","article-title":"Genetic and pharmacological inhibition of the nuclear receptor RORalpha regulates T(H)17 driven inflammatory disorders","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2024.102431_sref119","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.survophthal.2021.04.006","article-title":"Corneal collagen as a potential therapeutic target in dry eye disease","volume":"67","author":"Baratta","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.coph.2024.102431_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.705623","article-title":"Collagen mimetic peptides promote corneal epithelial cell regeneration","volume":"12","author":"Baratta","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2024.102431_bib121","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.4049\/jimmunol.1402166","article-title":"ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages","volume":"194","author":"Herova","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.coph.2024.102431_bib122","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jtos.2020.04.011","article-title":"RvE1 uses the LTB(4) receptor BLT1 to increase [Ca(2+)](i) and stimulate mucin secretion in cultured rat and human conjunctival goblet cells","volume":"18","author":"Yang","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.coph.2024.102431_bib123","article-title":"Evaluation\u00a0of novel YP-P10 Peptide in animal models of inflammatory dry eye disease","author":"Park","year":"2022","journal-title":"ARVO Annual Meeting Abstract"},{"key":"10.1016\/j.coph.2024.102431_bib124","series-title":"YP-P10 Peptide selectively decreased Th2 and Th17 cells in an in\u00a0vitro model of human blood-derived effector CD4+T-cell subsets","author":"Calder","year":"2023"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489224000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489224000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:58:25Z","timestamp":1761461905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489224000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":124,"alternative-id":["S1471489224000018"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2024.102431","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel treatments for dry eye syndrome","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2024.102431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102431"}}